Katsutoshi Oda

Summary

Affiliation: University of Tokyo
Country: Japan

Publications

  1. ncbi Cytodiagnostic problems in uterine sarcoma. Analysis according to a novel classification of tumor growth types
    Katsutoshi Oda
    Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Acta Cytol 48:181-6. 2004
  2. ncbi PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation
    Katsutoshi Oda
    Cancer Research Institute, Howard Hughes Medical Institute, University of California at San Francisco, San Francisco, California, USA
    Cancer Res 68:8127-36. 2008
  3. ncbi Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas
    Keiko Shoji
    Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
    PLoS ONE 7:e37431. 2012
  4. ncbi hScrib, a human homologue of Drosophila neoplastic tumor suppressor, is a novel death substrate targeted by caspase during the process of apoptosis
    Kenbun Sone
    Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Genes Cells 13:771-85. 2008
  5. ncbi Regulation of SIRT1 determines initial step of endometrial receptivity by controlling E-cadherin expression
    Akira Shirane
    Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Hongo 7 3 1 Bunkyo ku, Tokyo 113 8655, Japan
    Biochem Biophys Res Commun 424:604-10. 2012
  6. ncbi Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer
    Yuji Ikeda
    Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
    Int J Gynecol Cancer 22:725-31. 2012
  7. ncbi Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines
    Yuichiro Miyamoto
    Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113 8655, Japan
    Oncol Rep 29:51-7. 2013
  8. ncbi Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner
    Ayumi Taguchi
    Department of Obstetrics and Gynecology, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Vaccine 30:5368-72. 2012
  9. ncbi Retreatment with nedaplatin in patients with recurrent gynecological cancer after the development of hypersensitivity reaction to carboplatin
    Takahide Arimoto
    Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
    J Obstet Gynaecol Res 39:336-40. 2013
  10. ncbi The prevalence of cervical regulatory T cells in HPV-related cervical intraepithelial neoplasia (CIN) correlates inversely with spontaneous regression of CIN
    Satoko Kojima
    Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, Bunkyo ku, Tokyo, Japan
    Am J Reprod Immunol 69:134-41. 2013

Collaborators

Detail Information

Publications24

  1. ncbi Cytodiagnostic problems in uterine sarcoma. Analysis according to a novel classification of tumor growth types
    Katsutoshi Oda
    Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Acta Cytol 48:181-6. 2004
    ..To clarify the cytologic diagnostic problems of uterine sarcomas and the differential properties between pure sarcomas and carcinosarcomas...
  2. ncbi PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation
    Katsutoshi Oda
    Cancer Research Institute, Howard Hughes Medical Institute, University of California at San Francisco, San Francisco, California, USA
    Cancer Res 68:8127-36. 2008
    ..Our data therefore suggest that in tumors with co-occurring mutations in multiple components of the PI3K pathway, selective inhibition of the alpha isoform of p110 is an attractive therapeutic strategy, especially for late-stage tumors...
  3. ncbi Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas
    Keiko Shoji
    Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
    PLoS ONE 7:e37431. 2012
    ..Our data suggest that mutational statuses of PTEN and K-Ras might be useful predictors of sensitivity to NVP-BEZ235 in certain endometrial carcinomas...
  4. ncbi hScrib, a human homologue of Drosophila neoplastic tumor suppressor, is a novel death substrate targeted by caspase during the process of apoptosis
    Kenbun Sone
    Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Genes Cells 13:771-85. 2008
    ..These results indicate that caspase-dependent cleavage of hScrib is a critical step for detachment of cell contact during the process of apoptosis...
  5. ncbi Regulation of SIRT1 determines initial step of endometrial receptivity by controlling E-cadherin expression
    Akira Shirane
    Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Hongo 7 3 1 Bunkyo ku, Tokyo 113 8655, Japan
    Biochem Biophys Res Commun 424:604-10. 2012
    ....
  6. ncbi Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer
    Yuji Ikeda
    Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
    Int J Gynecol Cancer 22:725-31. 2012
    ..Although the prognosis of DP without any metastases is significantly better than that of SPM, pathological diagnosis is difficult in tumors with similar histological features...
  7. ncbi Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines
    Yuichiro Miyamoto
    Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113 8655, Japan
    Oncol Rep 29:51-7. 2013
    ....
  8. ncbi Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner
    Ayumi Taguchi
    Department of Obstetrics and Gynecology, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Vaccine 30:5368-72. 2012
    ....
  9. ncbi Retreatment with nedaplatin in patients with recurrent gynecological cancer after the development of hypersensitivity reaction to carboplatin
    Takahide Arimoto
    Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
    J Obstet Gynaecol Res 39:336-40. 2013
    ..The purpose of this retrospective study was to investigate the feasibility of replacing carboplatin with nedaplatin in patients who had developed a hypersensitivity reaction to carboplatin...
  10. ncbi The prevalence of cervical regulatory T cells in HPV-related cervical intraepithelial neoplasia (CIN) correlates inversely with spontaneous regression of CIN
    Satoko Kojima
    Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, Bunkyo ku, Tokyo, Japan
    Am J Reprod Immunol 69:134-41. 2013
    ..PD-1 expression on T cells induces Tregs. No studies have quantitatively analyzed the Tregs and PD-1+ cells residing in CIN lesions...
  11. ncbi Repression of estrogen receptor beta function by putative tumor suppressor DBC1
    Satoshi Koyama
    Department of Obstetrics and Gynecology, The University of Tokyo, Tokyo 113 8655, Japan
    Biochem Biophys Res Commun 392:357-62. 2010
    ..These results implicate the principal role of DBC1 in regulating ERbeta-dependent gene expressions...
  12. ncbi Resveratrol promotes expression of SIRT1 and StAR in rat ovarian granulosa cells: an implicative role of SIRT1 in the ovary
    Yoshihiro Morita
    Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, 7 3 1, Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Reprod Biol Endocrinol 10:14. 2012
    ..To date, the presence and physiological role of SIRT1 in the ovary are not known. Here we found that SIRT1 was localized in granulosa cells of the human ovary...
  13. ncbi Loss of Hugl-1 expression associates with lymph node metastasis in endometrial cancer
    Tetsushi Tsuruga
    Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113 8655, Japan
    Oncol Res 16:431-5. 2007
    ..These results indicate that loss of Hugl-1 expression in endometrial cancer may contribute to lymph node metastasis and it can be a factor of poor prognosis...
  14. ncbi Analysis of the status of the novel estrogen receptor α (ERα) coactivator p72 in endometrial cancer and its cross talk with erbB-2 in the transactivation of ERα
    Lin Zhao
    Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, Tokyo 113 8655, Japan
    Mol Med Report 1:387-90. 2008
    ..These findings also suggest that the cooperative transactivation of ERα AF-1 by the overexpression of p72, AIB1 and erbB-2 might be involved in tamoxifen-stimulated growth of endometrial cancer...
  15. ncbi Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report
    Keiko Shoji
    Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, 7 3 1 Hongo Bunkyo ku, Tokyo, 113 8655, Japan
    Med Oncol 28:771-4. 2011
    ..Anastrozole was effective to recurrent low-grade ESS even after being refractory to progestin therapy. Aromatase inhibitor treatment may be a useful option as a second-line hormonal treatment to low-grade ESS...
  16. ncbi High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma
    Katsutoshi Oda
    Cancer Research Institute, University of California San Francisco, San Francisco, California 94115, USA
    Cancer Res 65:10669-73. 2005
    ..Our data suggest that the PI3K pathway is extensively activated in endometrial carcinomas, and that combination of PIK3CA/PTEN alterations might play an important role in development of these tumors...
  17. ncbi Human homolog of Drosophila tumor suppressor Scribble negatively regulates cell-cycle progression from G1 to S phase by localizing at the basolateral membrane in epithelial cells
    Kazunori Nagasaka
    Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Cancer Sci 97:1217-25. 2006
    ..Our findings suggest the possibility that hScrib is involved in signal transduction to negatively regulate cell proliferation by localizing at the basolateral membrane of epithelial cells through LRRs and PDZ domains...
  18. ncbi Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer
    Takahide Arimoto
    Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo, 113 8655, Japan
    Med Oncol 29:1253-4. 2012
    ..On the other hand, single-agent chemotherapy would be better than this regimen considering its low response rate and severe hematological toxicity for patients with progression-free interval less than 6 months...
  19. ncbi Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers
    Kei Kawana
    Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7 3 1 Hongo, Bunkyo ku, 113 8655, Tokyo 113 8655, Japan
    Vaccine 21:4256-60. 2003
    ..1mg group and the placebo group recipients. This study suggests the L2-108/120 peptide is tolerable in humans and has the potential as a broad-spectrum prophylactic vaccine against genital HPV...
  20. ncbi Glomus tumor of the ovary: a case report
    Daichi Maeda
    Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Int J Surg Pathol 18:557-60. 2010
    ..Although an ovarian glomus tumor is extremely rare, the authors believe that it should be included in the differential diagnosis of ovarian mesenchymal tumors and sex cord tumors...
  21. ncbi Comparison between conventional surgery and radiotherapy for FIGO stage I-II cervical carcinoma: a retrospective Japanese study
    Hideomi Yamashita
    Department of Radiology, University of Tokyo Hospital, 7 3 1 Hongo, Bunkyou ku, Tokyo 113 8655, Japan
    Gynecol Oncol 97:834-9. 2005
    ..To compare treatment outcome results of conventional surgery vs. radiotherapy (RT) for carcinoma of the uterine cervix...
  22. ncbi Distinct lymphatic spread of endometrial carcinoma in comparison with cervical and ovarian carcinomas
    Koji Matsumoto
    Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan
    Cancer Lett 180:83-9. 2002
    ..Interestingly, EC can directly metastasize to both PLN and ALN with PLN metastases being dominant, a distinct lymphatic spread pattern better viewed as being somewhere between CC and OC...
  23. ncbi Weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer: a preliminary result of 19 cases
    Yuji Ikeda
    Department of Obstetrics and Gynecology, Ohki Memorial Kikuchi Cancer Center for Women, Tokorozawa, Saitama, Japan
    Int J Gynecol Cancer 23:355-60. 2013
    ..Here, we evaluated the effect of weekly low-dose administration of GEMOX in combination with bevacizumab (B-GEMOX) for patients with recurrent and refractory ovarian cancers (ROCs)...
  24. ncbi Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7
    Katsuyuki Adachi
    Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Vaccine 28:2810-7. 2010
    ..This novel approach at a therapeutic HPV vaccine may achieve more effective clinical responses through its induction of mucosal E7-specific CTL...